Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.
from Reuters: Company News https://ift.tt/2Nue4yV
via IFTTT
0 comments:
Post a Comment